Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Tax Provisions (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Tax Provisions for 16 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 144.41% to -$1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $652000.0 through Dec 2025, down 88.9% year-over-year, with the annual reading at $672000.0 for FY2025, 88.48% down from the prior year.
  • Tax Provisions for Q4 2025 was -$1.0 million at Anika Therapeutics, down from $900000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $8.2 million in Q4 2023, with the low at -$3.4 million in Q4 2021.
  • Average Tax Provisions over 5 years is $633550.0, with a median of $66000.0 recorded in 2024.
  • The sharpest move saw Tax Provisions plummeted 271.04% in 2022, then soared 534.0% in 2024.
  • Over 5 years, Tax Provisions stood at -$3.4 million in 2021, then soared by 234.08% to $4.5 million in 2022, then skyrocketed by 80.63% to $8.2 million in 2023, then crashed by 71.45% to $2.3 million in 2024, then plummeted by 144.41% to -$1.0 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$1.0 million, $900000.0, and $700000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.